This paper describes the development of a stability-indicating reversed-phase-high performance liquid chromatography (RP-HPLC) method for balofl oxacin (BFX) in the presence of its degradation products generated from forced decomposition studies. The drug substance was found to be susceptible to stress conditions of acid, base, oxidation, wet heat, and photo degradation. The drug was found to be stable to the dry heat condition attempted. Successful separation of the drug from the degradation products formed under stress conditions was achieved on a Zorbax C 18 column (150 mm × 4.6 mm id, 5 microns particle size) using methanol-water pH adjusted to 2.5 by orthophosphoric acid (40:60, v/v) as the mobile phase at a fl ow rate of 0.5 mL/min at 30°C temperature. Quantifi cation was achieved with photodiode array detection at 293 nm over the concentration range 50-150 μg/ml with mean recovery of 100.0 ± 0.53% for BFX by the RP-HPLC method. Statistical analysis proved the method is repeatable, specifi c, and accurate for estimation of BFX. Because the method could effectively separate the drug from its degradation products, it can be used as a stability-indicating method.
INTRODUCTION
Balofl oxacin (BFX) is an orally active of third generation fl uoroquinolone antibiotic. The chemical name of BFX 1, 2 is 1-cyclopropyl-6-fluoro-1, 4-dihydro-8 methoxy-(methylamino1-piperidinyl)-4-oxo-3-quinoline carboxylic acid and its molecular formula is C 20 H 24 FN 3 O 4 . BFX is a fl uoroquinolone that has a broader spectrum of activity and reduced toxicity than other fl uoroquinolones and structure of BFX shown in Figure 1 . BFX is used for the treatment of urinary tractinfection. 3 It exhibits excellent antibacterial activity against Gram-positive bacteria such as multiple drugresistant, staphylococci, and pneumococci; BFX acts by binding and inhibiting topoisomerase-II (deoxyribonucleic acid [DNA]-gyrase) and topoisomerase-IV enzymes, which are responsible for the coiling and uncoiling of DNA, which is needed for bacterial cell repair and replication. 4 Few analytical methods were reported in the literature, such as fl uorescent spectroscopy, 5 reversed-phase-high performance liquid chromatography (RP-HPLC) with fl uorescence detection, 6 liquid chromatography-electron ionization mass spectrometry, 7 luminescence spectroscopy 8 methods have been developed for the determination of BFX either in bulk or tablet formulations. However, no stability indicating RP-HPLC method is available for estimation of BFX in bulk and its pharmaceutical dosage form.
MATERIALS AND METHODS
Balofl oxacin pure drug was obtained as a gift sample from Hetero Labs Pvt. Ltd., Hyderabad Andhra Pradesh, India. Balofox-100 Mg tablets are manufactured by Hetero Pvt. Ltd., Himachal Pradesh, India and marketed by Abbott Health Care Pvt. Ltd., Mumbai, India. Balofl ox-100 mg tablets manufactured by Hetero Mumbai, India were procured from the local pharmacy. High performance liquid chromatography (HPLC) grade methanol and water (fi ltered through 0.2 μ fi lters) were purchased from
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Merck, Mumbai, India. Orthophosphoric acid (OPA) was purchased from Rankem, RFCL Ltd., New Delhi, India.
Preparation of solutions
A volume of 1000 ml of HPLC grade water (fi ltered through 0.2 μ fi lters) was degassed and adjusted the pH to 2.5 by 0.1 M OPA.
Preparation of stock solution
A total of 100 mg of BFX pure drug was dissolved in 100 mL of HPLC grade methanol to get a concentration of 1000 μg/ml.
Preparation of working standard solution
A volume of 10 ml of stock solution was taken in 100 ml volumetric fl ask and diluted up to the mark with HPLC grade water to get a concentration of 100 μg/ml.
Preparation of sample solution
A total of 20 tablets of BFX were powdered and an amount of the powder equivalent to 100 mg of the drug was accurately weighed and transferred to the 100 ml volumetric fl ask, made up to the volume with methanol. The solution was placed in an ultrasonicator for 20 min and fi ltered through a 25 mm, 0.45 μm nylon syringe fi lter. 10 ml of this solution was taken and diluted to 100 ml by using a HPLC grade water to get a fi nal concentration of 100 μg/ml. Five replicate sample solutions were prepared in a similar manner.
Instrumentation
Waters HPLC system consisting of a WATERS 2695 separation module, an inbuilt auto sampler, a column oven and WATERS 2996 photodiode array detector was employed for throughout the analysis. Chromatography was performed on a Zorbax C 18 -5 μm, 150 mm × 4.6 mm column. A Digisum DI 707 digital pH meter used for pH adjustment and a band line sonerex sonicator was used for sonication. The data were acquired using the Empower 2 software and other details of the instrumentation are given in Table 1 .
Optimized chromatographic conditions
Chromatography was performed on a Zorbax C 18 -5 μm, 150 mm × 4.6 mm column using mobile phase containing a mixture of HPLC water pH adjusted to 2.5 with OPA: Methanol 60:40%v/v. The mobile phase was filtered through the membrane filter (0.45 μm) and vacuum degassed by sonication prior to use. The pump pressure and run time was maintained at 1500-2000 psi and 10 min respectively. Chromatography was performed at ambient temperature (30°C) under isocratic conditions at a fl ow rate is 0.5 ml/min and detection was done at 293 nm. Instrumentation and optimized chromatographic conditions for proposed method details are shown in Table 1 .
Forced degradation sample study/specifi city
The study was intended to ensure the separation of BFX and its degradation products. Forced degradation study was performed to evaluate the stability indicating properties and specifi city of the method. 9 As per the ICH guideline Q2(R1) 10 provides the stress conditions to be performed for degradation products, which states that the stress samples should be stored under relevant stress conditions such as light, heat, humidity, acid/base hydrolysis, and oxidation. As per the guideline multiple stress studies were performed as indicated below and they were chromatographed along with anunstressed sample. 
Acid induced degradation
Solution containing 100 mg of BFX was treated with 10 mL 1N HCl sonicated or refl ex for 30 min and then add 10 ml of 1N NaOH to neutralize and make up with methanol (diluent).
Base induced degradation
Solution containing 100 mg of BFX was treated with 10 mL 1N NaOH sonicated or refl ex for 30 min and then add 10 ml of 1N HCL to neutralize and make up with methanol (diluent).
Oxidative condition
Hydrogen peroxide induced degradation. Solution containing 100 mg of BFX was treated with 6% w/v H 2 O 2 at 40°C for 6 h was cooled and diluted with methanol.
Photolytic degradation study
A total of 100 mg of BFX was exposed to the ultraviolet light/sunlight for 7 days. This drug powder was transferred in 50 ml volumetric fl ask, diluted to the volume with methanol.
Aqueous degradation study
A total of 100 mg of BFX was added to 25 ml of water and refl uxed for 6 h at 60°C after cooling make up the volume to 50 ml with methanol.
RESULTS AND DISCUSSION

Assay of B tablets
The developed method was applied to the assay of BFX tablets. The content was calculated as an average of six determinations, and experimental results were given in Table 2 . The results were very close to the labeled value of commercial tablets. There presentative standard and sample chromatograms of BFX were shown in Figures 2 and 3 , respectively.
Validation study of balofl oxacin
The Method validation was performed as per ICH guidelines 11 for the determination of BFX in bulk and in the pharmaceutical dosage forms. The method was validated with respect to parameters, including specifi city, accuracy, precision, linearity, robustness, system suitability, limit of detection (LOD), and limit of quantifi cation.
Specifi city
The specifi city was examined for non-degraded and degraded samples the solutions of after stress conditions of acid hydrolysis at 363 K, oxidation (H 2 O 2 ). The HPLC method for determination of BFX was found selective in the presence of degradation products as shown in Figure 4 . Peaks were symmetrical, clearly separated from each other [ Figure 4 ]. Photodiode array detection was used as an evidence of the specifi city of the method and to evaluate the homogeneity of BFX peaks. The peak purity values were more than 98.79% for BFX at 273 nm, which proves that degradants were not interfering with the main peak. Forced degradation results are given in Table 3 .
Accuracy (Recovery studies)
The accuracy was determined by calculating the recovery of BFX at 50%, 100%, and 150% was added to a prequantifi ed sample solution. The recovery studies were carried out in the tablet in triplicate each in the presence of placebo. The mean percentage recovery of BFX at each level was not <99% and not more than 101%. The percentage recovery of BFX was found to be in the range of 100-101%. The results are shown in Table 4 .
Precision
Precision should be investigated using homogeneous, authentic samples. Precision of the analytical method was expressed as a standard deviation and percentage of relative standard deviation of the series of replicate measurements. Precision of BFX estimation by the proposed method was ascertained by replicate analysis of homogeneous samples of BFX standard solutions in the intraday under the similar conditions. The system precision and method precision results were shown in Table 5 .
Linearity
Linearity of the proposed method was established by using series of standard solutions of BFX at concentration levels from 50 to 150%, such as 50%, 75%, 100% 125%, and 150%. This linearity studies are repeated for 3 times with different stock solutions. The curve obtained by concentration on x-axis and peak area on y-axis against showed linearity in the concentration range of 50-150 μg/ml of BFX and linearity graph is shown in Figure 1 . The regression equation was found to be y = 30635x Table 6 .
Robustness
The robustness was evaluated by the analysis of BFX under different experimental conditions such as slight changes in chromatographic conditions such as change of fl ow rate (±0.2 ml/min), temperature (±5°C), and mobile phase composition (±5%). It was observed that there were no marked changes in the chromatograms, and the parameters are within the limit, which indicates that the method has the robustness and suitability for routine use. The complete results are shown in Table 7 , and the method is having a good system suitability.
System suitability
The system suitability test was carried out on freshly prepared BFX standard solution (100%) was used for the evaluation of the system suitability parameters such as area, retention time, unique selling proposition peak tailing, and the number of theoretical plates, LOD and limit of quantitation (LOQ). Five replicate injections for a system suitability test were injected into the chromatographic system.
LOD
The LOD has established the minimum concentration at which analyze can be reliably detected. LOD is determined by the signal to noise ratio and signal to noise ratio 3:1 is generally considered acceptable for estimating the detection limit, and it was found to be 1.1 μg/ml.
LOQ
The LOQ has established the minimum concentration at which analyte can be reliably quantifi ed. LOQ is determined by the signal to noise ratio, and a typical signal to noise ratio is 10:1 is acceptable for estimating the quantitation limit and it was found to be 3.7 μg/ml. Finally, the proposed method is having a good system suitability and system suitability parameters as shown in Table 8 .
CONCLUSION
A stability-indicating RP-HPLC method was developed, validated and applied for the determination of BFX in pharmaceutical dosage forms. The developed method was validated and as per ICH guidelines and was found to be accurate, precise, robust, and specifi c. The chromatographic elution step is undertaken in a short time (<4 min). No interference from any components of pharmaceutical dosage form or degradation products was observed, and the method has been successfully used to perform longterm and accelerated stability studies of BFX formulations. Therefore, the method is suitable for use the routine quality control analysis of BFX in application programming interface or in pharmaceutical dosage forms. 
